EDX Medical is hosting a live investor presentation today after a run of commercial updates, led by a three-year employee health screening contract with Arnold Clark Group.

EDX Medical Group plc (LSE:EDX) is holding a live investor presentation via Investor Meet Company on Wednesday 14 October 2026 at 14:30 BST, open to existing and potential shareholders. The session is being presented by Professor Sir Chris Evans, Chief Scientific Officer. The Cambridge-based diagnostics company, which is quoted on AIM, was among the stocks drawing investor attention today.

The presentation follows a busy few months of company news. The most notable item was announced on 17 September 2026: an initial three-year agreement to deliver EDX's health and wellbeing screening programme to staff at Arnold Clark Group, with testing sessions at Arnold Clark premises from October 2026. EDX (LSE:EDX) also raised approximately £2.7m in August and continues to act as lead delivery partner on the Scottish Prostate Cancer Initiative. No regulatory announcement after 1 October 2026 was found, and the content of today's presentation was not available at the time of writing.

The Arnold Clark contract

The agreement covers 11,600 people across 200 locations in the UK. EDX will use proprietary biomarker panels covering more than 220 disease conditions, plus general health checks. Participation is voluntary. The contract builds on the employee health screening service EDX launched in July, which the August fundraising was designed to expand.

EDX said it expects annual revenues of "£1.4 and £1.6million" based on high anticipated participation. That figure is a company expectation rather than contracted revenue, and it depends on how many employees take part.

Professor Sir Chris Evans, OBE, founder of EDX Medical, said: "We are delighted to enter into this agreement with the Arnold Clark Group". He added: "A healthy workforce provides great benefits to both employees and employers." Russell Borrie, CEO of Arnold Clark Group, said: "we are wholeheartedly encouraging employees to take advantage of this programme."

The business behind the contract

EDX develops and supplies clinical and digital diagnostics products and services for the early detection and treatment of major diseases. It operates laboratories in Cambridge and offers an employee health screening programme to employers. The company was founded by Professor Sir Christopher Evans, OBE, and Chief Executive Dr Mike Hudson.

The shares moved to AIM on 13 May 2026 from the Apex Segment of the Aquis Stock Exchange Growth Market. Other 2026 commercial announcements included:

  • "EDX Medical service agreement with Astron Health" (8 July 2026)
  • "Launch of employee health screening service" (15 July 2026)
  • "Full launch of bowel cancer testing service (BC95)" (21 July 2026)
  • "Rapid pneumonia test deployed for NHS patients" (3 August 2026)

EDX is lead delivery partner and PSA test supplier for the Scottish Prostate Cancer Initiative, launched in March 2026 by Sir Chris Hoy. The initiative aims to test 25,000 men in Scotland. Over 12,500 men were tested in Phase 1, from the end of March to June 2026. Phase 2 began on 27 August 2026, with 31 testing sessions running until November 2026. Findings will be shared with NHS Scotland once analysis is complete. No revenue figure has been stated for this work.

Professor Sir Chris Evans said in August: "We are delighted that the Initiative is proving so popular both with the general public and employers."

Funding and the financial position

On 24 August 2026, EDX raised approximately £2.7m through a subscription for 19,378,563 new ordinary shares at 14p per share. Each Subscription Share carries warrants over 2 ordinary shares at an exercise price of 3p per Warrant, exercisable from 20 July 2028 to 19 July 2029. Proceeds are earmarked for expanding the employee health screening service. After the fundraising, 431,373,146 Ordinary Shares were in issue. Professor Sir Chris Evans said: "Investors in the Company have again demonstrated their confidence in the Company's strategy".

The annual report for the year ended 31 March 2026, published on 3 September 2026, showed:

  • Revenue of £330,541 (2025: £122,608)
  • Gross loss of £146,650 (2025: gross profit of £29,443)
  • Operating loss of £5,843,608 (2025: £4,250,243)
  • Loss for the year of £5,757,996 (2025: £3,594,391)
  • Cash and cash equivalents of £2,915,765 (2025: £2,402,630)
  • Net assets of £2,165,324

The company deferred £860,000 of revenue recognition into the current financial year following discussion with its auditors, because order processing ran past the year end. It raised £5.5 million through new share issues during the year. Chairman Jason Holt said: "We are still in the early stages of our commercial operations and have a high degree of confidence about the future."

At the AGM on 28 September 2026, all 13 resolutions were passed on a poll.

Share price and ownership

On 14 October 2026, the shares were shown at 8.75p, with a bid/ask spread of 8.00/9.50 and no trades recorded at the time of checking, so the price is likely the last close. The 52-week range runs from a low of 8.25p (02-Oct-2026) to a high of 12.75p (24-Aug-2026). The current price is below the 14p subscription price paid in August. Market data also showed a lower share count than the 431,373,146 confirmed by the company, so that market value figure is not used here.

A Director/PDMR shareholdings announcement on 4 September 2026 showed Professor Sir Christopher Evans holding 136,220,293 shares (31.58%) and Dr Michael Hudson holding 20,650,000 shares (4.79%). The same announcement disclosed 58,770 shares bought by Sir Christopher on market in 2025–January 2026 that were not reported at the time because of an administrative oversight.

Risks to weigh

  • Early-stage economics: revenue of £330,541 compares with a loss of £5,757,996 for the year to 31 March 2026.
  • Funding and dilution: repeated share placings, including £5.5 million in FY2026 and approximately £2.7m in August 2026, plus outstanding warrants.
  • Contract uncertainty: the Arnold Clark revenue is an expectation that relies on voluntary participation.
  • Ownership concentration: the founder holds 31.58% of the shares.
  • Liquidity: a wide spread and thin trading can make prices volatile.
  • Sector risk: diagnostics companies face clinical validation, regulatory and NHS procurement risks.

What to watch next

  • Any update following today's Investor Meet Company presentation
  • Progress on Arnold Clark testing sessions, which begin from October 2026
  • Completion of Phase 2 of the Scottish Prostate Cancer Initiative in November 2026
  • Evidence of how much of the deferred £860,000 of revenue is recognised in the current year